White-coat hypertension: The neglected subgroup in hypertension

Korean Circulation Journal

Volumn 48, Issue 7, 2018, Pages 552-564

  Cuspidi, Cesare ^a,b   Tadic, Marijana ^c   Mancia, Giuseppe ^a   Grassi, Guido ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

Anti hypertensive treatment; Cardiovascular prognosis; White coat hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; LACIDIPINE;

ALL CAUSE MORTALITY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HOME MONITORING; HUMAN; HYPERTENSION; PREVALENCE; PROGNOSIS; REVIEW; WHITE COAT HYPERTENSION;

EID: 85049411842     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2018.0167     Document Type: Review

References (43)

1. INTRODUCTION
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357. PUBMED | CROSSREF
3. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. Ambulatory Blood Pressure Monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults. Chronobiol Int 2015;32:1329-42. PUBMED | CROSSREF
4. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988;259:225-8. PUBMED | CROSSREF
5. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995;13:1377-90. PUBMED | CROSSREF
6. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018;71:e13-115.
7. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731-68. PUBMED | CROSSREF
8. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study). Circulation 2001;104:1385-92. PUBMED | CROSSREF
9. Afsar B. Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension. J Cardiol 2013;61:222-6. PUBMED | CROSSREF
10. Mulè G, Nardi E, Cottone S, et al. Metabolic syndrome in subjects with white-coat hypertension: impact on left ventricular structure and function. J Hum Hypertens 2007;21:854-60. PUBMED | CROSSREF
11. Tocci G, Presta V, Figliuzzi I, et al. Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database. J Clin Hypertens (Greenwich) 2018;20:297-305. PUBMED | CROSSREF
12. de la Sierra A, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens 2017;35:2388-94. PUBMED | CROSSREF
13. Vyssoulis G, Karpanou E, Adamopoulos D, et al. Nocturnal blood pressure fall and metabolic syndrome score in patients with white coat hypertension. Blood Press Monit 2008;13:251-6. PUBMED | CROSSREF
14. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009;27:1672-8. PUBMED | CROSSREF
15. Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension. Hypertension 2007;50:537-42. PUBMED | CROSSREF
16. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015;116:976-90. PUBMED | CROSSREF
17. Cuspidi C, Facchetti R, Bombelli M, et al. Risk of new onset metabolic syndrome associated with white coat and masked hypertension: data from a general population. J Hypertens. 2018. [Epub ahead of print].
18. Sivén SS, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study. J Hypertens 2016;34:54-60. PUBMED | CROSSREF
19. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009;54:226-32. PUBMED | CROSSREF
20. Palatini P, Dorigatti F, Roman E, et al. White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study. J Hypertens 1998;16:977-84. PUBMED | CROSSREF
21. Cuspidi C, Meani S, Sala C, et al. How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring? J Hypertens 2007;25:315-20. PUBMED | CROSSREF
22. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. J Am Coll Cardiol 2016;68:2044-6. PUBMED | CROSSREF
23. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009;27:2458-64. PUBMED | CROSSREF
24. Høegholm A, Kristensen KS, Bang LE, Nielsen JW, Nielsen WB, Madsen NH. Left ventricular mass and geometry in patients with established hypertension and white coat hypertension. Am J Hypertens 1993;6:282-6. PUBMED | CROSSREF
25. Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G, Mancia G. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens 2015;33:24-32. PUBMED | CROSSREF
26. Manios E, Michas F, Stamatelopoulos K, et al. White-coat isolated systolic hypertension is a risk factor for carotid atherosclerosis. J Clin Hypertens (Greenwich) 2016;18:1095-102. PUBMED | CROSSREF
27. Mancusi C, Gerdts E, Losi MA, et al. Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). Int J Cardiol 2017;244:260-4. PUBMED | CROSSREF
28. Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. Blood Press Monit 2015;20:57-63. PUBMED
29. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846-53. PUBMED | CROSSREF
30. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013;62:168-74. PUBMED | CROSSREF
31. Mancia G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. Hypertension 2015;66:437-44. PUBMED | CROSSREF
32. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011;24:52-8. PUBMED | CROSSREF
33. Franklin SS, Thijs L, Hansen TW, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012;59:564-71. PUBMED | CROSSREF
34. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-69. PUBMED | CROSSREF
35. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016;34:593-9. PUBMED | CROSSREF
36. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018;378:1509-20. PUBMED | CROSSREF
37. Høegholm A, Wiinberg N, Kristensen KS. The effect of antihypertensive treatment with dihydropyridine calcium antagonists on white-coat hypertension. Blood Press Monit 1996;1:375-80. PUBMED
38. Bulpitt CJ, Beckett N, Peters R, et al. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension 2013;61:89-94. PUBMED | CROSSREF
39. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000;102:1139-44. PUBMED | CROSSREF
40. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension 2014;64:1388-98. PUBMED | CROSSREF
41. National Institute for Health and Clinical Excellence (UK). Hypertension in adults: diagnosis and management. Clinical guideline [Internet]. London: National Institute for Health and Clinical Excellence; 2011 [cited 2011 Aug]. Available from: www.nice.org.uk/guidance/CG127.
42. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 2017;33:557-76. PUBMED | CROSSREF
43. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res 2015;116:1034-45. PUBMED | CROSSREF